Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson’s Disease Participants in the Parkinson’s Progression Markers Initiative: A Cross-Sectional Study

BACKGROUND: There are limited data on the phenotypic and dopamine transporter (DAT) imaging characterization of the Parkinson’s disease (PD) patients with leucine rich kinase 2 (LRRK2) and glucosylceramidase beta (GBA) mutations. OBJECTIVE: The objective of this study was to examine baseline clinica...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mov Disord
Autors principals: Simuni, Tanya, Brumm, Michael C., Uribe, Liz, Caspell-Garcia, Chelsea, Coffey, Christopher S., Siderowf, Andrew, Alcalay, Roy, Trojanowski, John Q., Shaw, Leslie M., Seibyl, John, Singleton, Andrew, Toga, Arthur W., Galasko, Doug, Foroud, Tatiana, Nudelman, Kelly, Tosun-Turgut, Duygu, Poston, Kathleen, Weintraub, Daniel, Mollenhauer, Brit, Tanner, Caroline M., Kieburtz, Karl, Chahine, Lana M., Reimer, Alyssa, Hutten, Samantha, Bressman, Susan, Marek, Kenneth
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7231646/
https://ncbi.nlm.nih.gov/pubmed/32073681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mds.27989
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars